Science
Mechanism of Action
Palmitoylethanolamide (PEA) functions by engaging the endocannabinoid system within the skin. It primarily activates peroxisome proliferator-activated receptor alpha (PPAR-α) and interacts with cannabinoid receptors (CB1, CB2) and TRPV1 receptors. This intricate modulation inhibits mast cell activation and subsequent degranulation, which reduces the release of pro-inflammatory mediators like histamine, prostaglandin D2, and TNF-α. Additionally, PEA decreases the expression of COX-2 and iNOS. On a physiological level, this action translates to strengthened skin barrier function, reduced transepidermal water loss (TEWL), diminished visible redness, and enhanced skin hydration.
Research
Clinical Evidence
High confidenceN/A
Key findings
- 01 Topical application of a PEA-containing cream significantly improved multiple symptoms of atopic eczema, including erythema, pruritus, excoriation, scaling, lichenification, dryness, and overall itchiness, leading to improved sleep quality.
- 02 PEA-incorporated elastic nano-liposomes demonstrated efficient transdermal delivery, enhanced skin retention, increased cellular migration, and modulated genes associated with anti-nociceptive, anti-inflammatory, and skin barrier repair functions.
- 03 In canine skin mast cells, PEA dose-dependently inhibited the release of pro-inflammatory mediators (e.g., prostaglandin D2, TNF-α, histamine) within a concentration range of 10^-8 M to 10^-5 M.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
As a lipophilic molecule, PEA Palmitate is largely insoluble in water, which can present formulation challenges for efficient skin penetration, bioavailability, and overall stability. Advanced delivery systems like nano-liposomes can mitigate these issues.
Conflicts
- Must not be formulated in cosmetic products where the formation of N-nitroso compounds is possible.
Safety
Safety Profile
The CIR Expert Panel deemed ethanolamides, including PEA Palmitate, safe for topical use within current practices and concentrations, provided formulations are non-irritating and avoid N-nitroso compound formation. It is generally well-tolerated and has not exhibited mutagenic or genotoxic effects in studies. Topical application has been deemed possibly safe for durations up to 28 days. The FDA's approval for PEA to enter Phase 2a clinical trials for lung inflammation (via oral administration) further indicates its recognized safety profile.
Your Skin
Skin Compatibility
Our Assessment
Verdict
PEA Palmitate is a valuable ingredient for sensitive and compromised skin, offering robust anti-inflammatory and barrier-supporting benefits with a favorable safety profile.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources